Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ustekinumab biosimilar - Samsung Bioepis

Next Previous
X
Search
Drug Profile

Ustekinumab biosimilar - Samsung Bioepis

Alternative Names: Pyzchiva; SB-17

Latest Information Update: 04 Nov 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Samsung Bioepis
  • Developer Samsung Bioepis; Sandoz
  • Class Anti-inflammatories; Antineoplastics; Antipsoriatics; Antirheumatics; Antiulcers; Monoclonal antibodies; Skin disorder therapies
  • Mechanism of Action Interleukin 12 inhibitors; Interleukin 23 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Crohn's disease; Psoriatic arthritis; Ulcerative colitis
  • Registered Plaque psoriasis
  • No development reported Autoimmune disorders

Most Recent Events

  • 30 Oct 2024 Launched for Crohn's disease in European Union (SC)
  • 30 Oct 2024 Launched for Psoriatic arthritis in European Union (SC)
  • 30 Oct 2024 Launched for Ulcerative colitis in European Union (SC)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top